Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CDK7 | P50613 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | CCNH | P51946 | 3/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30549101 | 1.00 | BRD4 (0.45) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL21188476 | 0.90 | BRD4 (0.46) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL21178813 | 0.90 | BRD4 (0.46) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL24087358 | 0.90 | BRD4 (0.46) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL21178193 | 0.88 | BRD4 (0.44) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL21178259 | 0.87 | HTR6 (0.34) | BRD4CDK7CCNHDRD2HTR2A | |
| SCHEMBL21184433 | 0.85 | CDK7 (0.55) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL21184338 | 0.85 | CDK7 (0.55) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL24176336 | 0.83 | CDK7 (0.46) | BRD4CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL30771937 | 0.83 | CDK7 (0.46) | BRD4CCNT1CCNKCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | RECURSION PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-20240124504-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-18 | — | — | US | disclosed |
| EP-3740206-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11918592-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4269403-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269403-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| CN-116670123-A | Aromatic heterocyclic compound, pharmaceutical composition and application thereof | 湃隆生物科技有限公司（香港） | 2023-08-29 | — | — | CN | disclosed |
| WO-2022134641-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 湃隆生物科技有限公司（香港） | 2022-06-30 | — | — | WO | disclosed |
| WO-2022134642-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 湃隆生物科技有限公司（香港） | 2022-06-30 | — | — | WO | disclosed |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220000890-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
| EP-3740207-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3740206-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143730-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000890-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | BRD4 554/4885CCNT1 35/4885CCNK 3/4885 |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | BRD4 554/4885CCNT1 35/4885CCNK 3/4885 |
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK17, CDK8 | BRD4 132/4885CCNT1 48/4885CCNK 39/4885 |
| US-20240124504-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | CDK7, CDK17, CDK8 | BRD4 184/4885CCNT1 47/4885CCNK 33/4885 |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | CDK7, CDK17, CDK1 | BRD4 375/4885CCNT1 78/4885CCNK 4/4885 |
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK8, CDK6 | BRD4 90/4885CCNT1 21/4885CCNK 19/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | BRD4 554/4885CCNT1 35/4885CCNK 3/4885 |
| US-11918592-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | BRD4 554/4885CCNT1 35/4885CCNK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.